Teleflex buys vascular closure company Essential Medical

209
Manta

Teleflex has acquired Essential Medical, which has developed and commercialised the CE marked Manta vascular closure device—specifically designed for closure of large bore arteriotomies following procedures using devices or sheaths ranging in size from 10Fr to 18Fr (with maximum outer diameters up to 25Fr). In its CE mark study, a press release reports, the Manta device demonstrated rapid and reliable haemostasis with its resorbable collagen-based technology and complication rates that were non-inferior to surgical and suture-based closure methods.

Liam Kelly, president and CEO of Teleflex, states: “We are very excited to announce this acquisition, which expands our presence in the structural heart and endovascular aneurysm repair markets. The Manta vascular closure device represents a truly innovative solution to address closure-related complications and high costs associated with many large and rapidly growing interventional procedure categories, such as transcatheter aortic valve implantation (TAVI) and ventricular assist device implantation. Physician adoption of the Manta device in international markets has been impressive, with over 8,100 procedures completed to date across a number of countries in the EU. We believe we can leverage our strong presence in the interventional cardiology market to accelerate adoption and growth of this breakthrough technology worldwide. Following the anticipated FDA premarket approval of the Manta device in 2019, we expect the acquisition will be modestly accretive to our constant currency revenue growth and gross margins over a multi-year period.”

Greg Walters, Essential Medical’s co-founder, president and CEO, comments: “The combination of Teleflex and Essential Medical provides an excellent opportunity to maximise physician and patient access to the Manta vascular closure device. We are delighted to become an important part of Teleflex’s interventional cardiology business.”

(Visited 77 times, 1 visits today)

LEAVE A REPLY

Please enter your comment!
Please enter your name here